Details of the Drug Combinations

General Information of This Drug (ID: DMCJN1P)

• Drug Name: Plerixafor (DMCJN1P)
• Synonyms: Mozobil; AMD3100; Amd 3100; JM 2987; JM 3100; JM3100; SDZ SID 791; SID791; AMD-3100; Bicyclam JM-2987; JM-3100; Mozobil (TN); GNA & AMD-3100; HHA & AMD-3100; Plerixafor (INN/USAN); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA); 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane

Indication

Non-hodgkin lymphoma; ICD 11: 2B33.5; Status: Approved [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

9 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Cyclophosphamide + Plerixafor	DCM624E	Cyclophosphamide	Refractory Multiple Myeloma	[2]
Dexamethasone + Plerixafor	DCB4TIP	Dexamethasone	Multiple Myeloma	[3]
Plerixafor + Etoposide	DC6K6C6	Etoposide	Adult Acute Lymphoblastic Leukemia in Remission	[4]
Plerixafor + Decitabine	DC9WEEA	Decitabine	Acute Myeloid Leukemia	[5]
Plerixafor + Clofarabine	DCF45XK	Clofarabine	Acute Myelogenous Leukemia	[6]
Plerixafor + Bortezomib	DCK18D9	Bortezomib	Multiple Myeloma	[3]
Plerixafor + Azacitidine	DCXYJYV	Azacitidine	Myelodysplastic Syndromes	[7]
Plerixafor + Temozolomide	DCQC820	Temozolomide	Adult Ependymoblastoma	[8]
Ronacaleret + Plerixafor	DC21KYE	Ronacaleret	Transplantation, Stem Cell	[9]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 844).
• [2] ClinicalTrials.gov (NCT01074060) Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma
• [3] ClinicalTrials.gov (NCT00903968) Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
• [4] ClinicalTrials.gov (NCT01408043) Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
• [5] ClinicalTrials.gov (NCT01352650) Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)
• [6] ClinicalTrials.gov (NCT01160354) Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)
• [7] ClinicalTrials.gov (NCT01065129) Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)
• [8] ClinicalTrials.gov (NCT01977677) Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
• [9] ClinicalTrials.gov (NCT01802892) Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)